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ABSTRACT
High-dose therapy and autologous hematopoietic stem cell transplantation are standard early treatment of
patients with multiple myeloma. Tandem transplantation appears to provide additional benefit, particularly in
patients with limited response to initial transplantation. Myeloablative allogeneic transplantation provides the
only potential for cure, but has been largely abandoned because of high mortality rates. Newer and better
induction regimens, rigorous analysis of results with autologous and allogeneic transplantation, and the
development of risk-adapted stratification provide the impetus for this critical evaluation of the role of
hematopoietic stem cell transplantation in multiple myeloma.
© 2007 American Society for Blood and Marrow Transplantation
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NTRODUCTION
The median survival of patients with multiple my-
loma is approximately 4 years. This malignancy is
irtually incurable, and accounts for 20% of all deaths
ecause of hematologic malignancies. Further, it is a
rogressively debilitating disease characterized by
one pain, spontaneous fractures, frequent infections,
enal failure, and anemia. Because of its potential to
ramatically affect quality of life, the time spent in
emission is important. Despite controversy about the
ffectiveness and precise role of hematopoietic stem
ell transplantation (HSCT) in multiple myeloma, this
isorder is presently the most common for which
SCT is used. New transplant approaches including
ouble transplants, safer regimens for allogeneic trans-
lantation, and maintenance therapy may improve
utcome. The integration of newer agents including
halidomide, lenalidomide, and bortezomib into con-
entional treatment promises to improve nontransplant
pproaches, causing some to question the need for trans-
lantation. In this review, we summarize relevant back-
round information and discuss the role of hematopoi-
tic stem cell transplantation in multiple myeloma. aURRENT OUTCOMES WITH
UTOLOGOUS TRANSPLANTATION
ingle Autotransplantation
Large prospective randomized trials [1,2] and sev-
ral nonrandomized comparisons [3-8] established for
ost clinicians that in patients aged 65 or less with no
igniﬁcant organ impairment, high-dose therapy and
utologous transplantation following initial conven-
ional therapy improve rates of response, complete
emission (CR), overall survival (OS), and event-free
urvival (EFS) compared to continued conventional
herapy. Also, the time without symptoms, treatment
nd treatment toxicity (TWIsTT) was longer for pa-
ients who underwent transplantation [9]. Results of
utologous transplantation have improved largely
hrough reduction of transplant-related morbidity and
ortality (TRM) using modern supportive care, in-
luding the use of mobilized peripheral blood stem
ells in place of marrow and preparation with melpha-
an rather than radiation-containing regimens [10].
he TRM rate following autotransplantation is now
2%. A recent evidence-based review recommended
utotransplantation, using melphalan and peripheral
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S. Pant and E. A. Copelan878lood stem cells, in preference to standard chemo-
herapy as de novo treatment [11].
Some randomized studies comparing autotrans-
lantation to conventional therapy, however, have not
emonstrated a signiﬁcant survival beneﬁt [9,12-14].
he differences in outcome between trials (Table 1)
ay be related to variations in eligibility criteria, in-
uction therapy, preparative regimens, duration of
ollow-up, and the use of transplantation at relapse.
or example, the conditioning regimens vary and
hose used in some studies are probably subopti-
al(13). Beneﬁt from transplantation may not be de-
onstrable for several years, but some studies do not
rovide lengthy follow-up [13,14]. The Spanish Pro-
rama para el Tratamiento de Hemopatias Malignas
PETHEMA) group randomized only those patients
ho achieved a response to induction chemotherapy
14]. Yet patients who fail to respond, beneﬁt from
utotransplantation [15]. Despite these limitations of
he reports, it is important that a meta-analysis of
andomized controlled trials demonstrated a signiﬁ-
ant beneﬁt in progression-free survival (PFS), but not
S with a single early autotransplant [16]. It is rea-
able 1. Major Randomized Prospective Trials with Single Autologous
Trial Author Year
No. of
Patients
Media
Age
ntergroupe
Francophone du
Myelome 90
Attal, et al. (2) 1996 200 57
edical Research
Council
Myeloma VII
Child, et al. (1) 2003 401 55
OVON* Segeren et al. (13) 2003 261 55
ETHEMA† Blade, et al. (14) 2005 216 56
yelome
Autogreffe 91
Fermand et al. (9) 2005 190 61
ntergroup S 9321 Barlogie et al. (12) 2006 516 54
BI indicates total-body irridiation.
HOVON: Dutch-Belgian Hemato-Oncology Cooperative Study G
PETHEMA: Programa para el Tratamiento de Hemopatias Malionable to conclude that autotransplantation provides wsigniﬁcant beneﬁt in PFS and TWIsTT. A signiﬁ-
ant survival beneﬁt for early transplantation has not
een clearly demonstrated, but the frequent use of
ater transplantation complicates interpretation of this
nding.
ouble Autotransplantation
Barlogie and colleagues [17,18] introduced the
oncept of tandem transplants, which have subse-
uently been investigated in several randomized trials
19-23]. Attal and colleagues [21] compared single to
ouble autologous transplantation in patients under
0 years of age following 3 or 4 courses of chemo-
herapy. At 6 years, OS and EFS were doubled in the
andem transplant group. The survival beneﬁt was
agniﬁed in those with less than a very good partial
esponse (PR) following the ﬁrst transplant. These
esults were supported by a randomized prospective
tudy (Bologna 96) that demonstrated that tandem
SCT beneﬁts patients who are not in at least a near
R after the ﬁrst transplant [22]. Data from the Ar-
ansas group shows a survival advantage in patients
ell Transplantation in Multiple Myeloma
Conditioning
Regimen Survival
lphalan 140 and
TBI
Superior progression free survival (18 versus
27 mo., P  .01) and overall survival (37.4
mo. versus not reached) with transplant
versus conventional chemotherapy
lphalan 200 Superior progression free survival (31.6 mo.
versus 19.6 mo., P < .001) and overall
survival (54 mo. versus 42 mo., P  .04)
with transplant vs. conventional
chemotherapy
clophosphamide
120 mg/kg and
TBI
No difference in progression free survival (22
mo. versus 21 mo., P  .28) and overall
survival ( 47 mo. versus 50 mo., P  .41)
with transplant versus conventional
chemotherapy
lphalan 200,
Melphalan 140
and TBI
No difference in progression free survival (42
mo. versus 33 mo., P  .57) and overall
survival (61 mo. versus 66 mo., P  .89)
with transplant versus conventional
chemotherapy
lphalan 200,
melphalan 140
and busulphan
No difference in progression free survival
(25.3 mo. versus 18.7 mo., P  .07) and
overall survival (47.8 mo. versus 47.6 mo.,
P  .91) with transplant versus
conventional chemotherapy
lphalan 140 and
TBI
No difference in progression free survival (7
year estimate 17% and 16%.) and overall
survival ( 7 year estimate 37% and 42
%mo.) with transplant vsersus
conventional chemotherapyStem C
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Hematopoietic Stem Cell Transplantation in Multiple Myeloma 879istoric controls who underwent a single procedure. A
ecent update of patients undergoing tandem trans-
lantation at Arkansas demonstrated a 10-year EFS of
8% and OS of 23% [24].
Tandem transplants do require increased time in
he hospital and may not beneﬁt patients who achieve
R or very near CR after the ﬁrst transplantation
21,22]. The quality of life at 1 year appears worse
fter tandem transplantation [20]. Last, patients with
peciﬁc cytogenetic abnormalities may not beneﬁt
ubstantially from tandem transplantation [25,26].
Nevertheless, these studies established the beneﬁt
f double transplantation in most patients aged under
0 who have a limited response to a single transplant.
he second transplant should be performed within 3
o 6 months after the ﬁrst. Patients who do not com-
lete 2 transplants within 12 months have a worse
rognosis [24].
aintenance Therapy following
utologous Transplantation
Interferon maintenance following autotransplan-
ation initially seemed beneﬁcial [27,28], but many
atients experienced toxicity. Subsequent randomized
rials incorporating interferon failed to demonstrate a
igniﬁcant survival beneﬁt [12,29].
Thalidomide was used by the Arkansas group dur-
ng induction, between the 2 transplants, and follow-
ng transplantation until disease progression or signif-
cant adverse affects [30]. Thalidomide increased the
ates of response and EFS, but not OS, because of a
oorer outcome after relapse. Also, 30% of patients
aking thalidomide experienced a thrombotic event and
7% experienced grade 3 or 4 peripheral neuropathy.
The Intergroupe Francophone du Myelome
IFM) 99-02 study, which did not use thalidomide
arlier in treatment, demonstrated a beneﬁt in EFS
nd OS in patients randomized to thalidomide and
amidronate after tandem transplant. Adverse events
ecessitated discontinuation of thalidomide in 39% of
atients [31]. Thalidomide appeared to beneﬁt pa-
ients with residual disease following transplantation,
aising doubt about the appropriateness of the term
maintenance.” Lower doses of thalidomide are being
valuated after tandem transplantation [32]. The
resent common use of thalidomide in induction may
ompromise its effectiveness in maintenance. Bort-
zomib is also under investigation as maintenance
herapy [33].
lderly Patients
Most studies of autotransplantation in myeloma
ave been carried out in the nonelderly, thus exclud-
ng a large proportion of myeloma patients [34]. The
easibility and efﬁcacy of transplantation in patients
ver 70 years of age was demonstrated in a nonran- tomized study by the Arkansas group, utilizing a
ower dose of melphalan than is used in younger
atients [35]. A multicenter prospective study demon-
trated a higher response rate and signiﬁcantly better
FS and OS in patients undergoing tandem trans-
lants using intermediate dose melphalan [36].
In a trial of patients over 65 years of age, however,
halidomide in combination with melphalan and pred-
isone resulted in superior PFS and OS compared to
ransplantation following induction with melphalan and
rednisone [37]. This study did not address whether
utotransplantation following the more effective induc-
ion regimen would provide additional beneﬁt. Thus,
hereas transplantation can be safely performed and is
ffective in selected patients over the age of 65, its supe-
iority to present nontransplant approaches is uncertain.
iming of Transplantation
A prospective randomized study demonstrated
imilar survival in patients irrespective of whether
ransplantation was performed early or at the time of
elapse [38]. The TWiSTT, however, was better in
he group undergoing early transplantation. A non-
andomized study demonstrated that patients trans-
lanted within 1 year of primary therapy fared better
han those who underwent late transplant [39]. Based
n these data, autotransplantation should generally be
erformed early in the course of disease.
urging
CD34 selection reduced the tumor burden in the
raft by more than 3 logs, but PFS and OS were not
mproved [40]. A study of genetically marked grafts
emonstrated no contribution of infused myeloma
ells to relapse [41], emphasizing that the main cause
f relapse is the failure to eradicate myeloma in the
atient.
uality of Life
Myeloma is a debilitating disease with frequent
elapses. It can devastate quality of life. The Nordic
yeloma Group demonstrated lower quality of life
cores at 1 and 6 months in patients who underwent
ransplantation, but better scores in this group at 36
onths [42]. The TWiSTT score was better in the
ransplantation group compared to that receiving only
onventional chemotherapy in the Myelome-Au-
ogreffe (MAG) trial [9]. Quality of life is also better
hen patients undergo transplant early compared to
fter relapse [38]. It is vital that parameters assessing
he quality of life be included in the design of trials
tudying transplantation in multiple myeloma.
ost versus Benefit of Autotransplant
Early studies comparing the cost effectiveness of
ransplant to conventional chemotherapy were retro-
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S. Pant and E. A. Copelan880pective and involved small numbers of patients
43,44]. Gulbrandsen and colleagues [45] prospec-
ively compared melphalan-prednisone to autologous
ransplant. They used quality-adjusted life-years, a
roduct of 2 factors: the change in quality of life that
ollows from an intervention and the number of years
ained as a result of treatment. The cost of high-dose
herapy and stem cell transplantation was justiﬁed by
he considerable gain in patient’s quality-adjusted life-
ears.
URRENT OUTCOMES WITH
LLOGENEIC TRANSPLANTATION
yeloablative Transplantation
In contrast to autologous transplantation, allogeneic
ransplantation can cure patients with myeloma [46].
his approach assures the absence of myeloma cells in
he graft and provides the potential for a graft-versus-
yeloma effect [47]. The targets of graft-versus-my-
loma (and graft-versus-host disease [GVHD]) are mi-
or histocompatibility antigens recognized by donor
cells. T cell responses to antigens restricted to
ematopoietic cells can mediate an effective antitumor
eaction without GVHD. More widely expressed mi-
or histocompatibility antigens may be targets for
VHD and a graft-versus-myeloma effect. Following
donor lymphocyte infusion-induced sustained com-
lete remission in a patient with multiple myeloma,
an Bergen and colleagues [48] isolated a cytotoxic T
ymphocyte-clone capable of recognizing the minor
ntigen encoded by the ATP-dependent interferon
esponsive gene, which was highly expressed on the
yeloma cells. Expression of the relevant minor his-
ocompatibility antigens on malignant stem cells,
hose rare cells with the ability to perpetuate them-
elves through self-renewal and to generate differen-
iated malignant plasma cells, are probably required
or cure of malignancy by the allogeneic effect [49].
Allogeneic transplantation in patients with multi-
le myeloma has generally resulted in a high incidence
f TRM [12,46,50-53]. Mortality following unrelated
ransplantation has been particularly frequent [53].
llotransplantation does, however, signiﬁcantly lower
elapse rates [50], and a modest proportion of patients
ppear to be cured. Despite providing the only poten-
ial for cure, the substantial mortality rates, exceeding
0% in many studies, have been considered prohibi-
ive by most clinicians.
Generally, the high mortality rates have been as-
ociated with transplantation of patients with ad-
anced disease who had received multiple chemother-
py regimens. The Seattle group reported a mortality
ate in excess of 50%, but noted that for patients who
nderwent transplantation within a year from diagno-
is, mortality was 20% [50]. Early transplantation snd careful selection of patients is crucial to achieve
avorable outcomes using allogeneic transplantation in
ost hematologic malignancies [49]. These factors
ay be particularly critical in patients with myeloma
ho tolerate allotransplantation poorly, perhaps re-
ated to their underlying immunodeﬁciency and the
ebilitating nature of their disease. The recently pub-
ished U.S. intergroup trial originally included an al-
ogeneic transplant arm that was closed after 36 pa-
ients were treated, because of a mortality rate of 53%
12]. These allogeneic patients were treated, following
ompletion of induction chemotherapy with high-
ose cyclophosphamide to mirror the autologous
ransplantation arm of the trial. They subsequently
eceived preparation for transplantation with melpha-
an plus total body irridiation (TBI). The high-dose
yclophosphamide coupled with the intensive prepar-
tive regimen may have contributed to the high mor-
ality in this vulnerable population. Despite the early
eaths, 7-year survival is identical for autologous and
llogeneic recipients, and PFS is 22% for allogeneic
ecipients with a plateau extending up to 10 years.
ubstantially higher rates of sustained PFS following
llogeneic transplantation have been reported [51,52].
The European Group for Blood and Marrow
ransplantation compared results in patients with my-
loma who underwent allogeneic transplantation from
ully matched siblings from 1994 through 1998 to
hose who underwent transplantation prior to 1994
54]. Survival was signiﬁcantly improved in patients
ho underwent the procedure after 1994 because of a
igniﬁcant reduction in deaths from interstitial pneu-
onia and infections. Transplant-related mortality
as reduced to 21% at 6 months and 30% at 2 years,
ith no difference between those receiving bone mar-
ow or peripheral blood. The patients transplanted
fter 1994 beneﬁted from less previous treatment and
etter supportive care.
Although numerous myeloablative preparative
egimens have been used, their inﬂuence on outcome
as been inadequately studied. Prospective compari-
ons have not been performed. The suspicion that
BI may not be well tolerated by patients with myeloma
nd older individuals has led to extensive use of radia-
ion-free regimens, including bulsulfan and cyclophos-
hamide [50] and busulfan and melphalan [55].
The use of less toxic regimens is particularly crit-
cal in multiple myeloma. Dose adjustment [56]
nd/or intravenous administration of busulfan [57]
ppear to lower TRM rates and improve effectiveness
n other disorders. A large study of targeted busulfan
receding autotransplantation in myeloma reported
o venooclusive disease [58].
Considering recent results with lower mortality
ates, the absence of other curative treatments, and the
ebilitating nature of this disease, allotransplantation
eems understudied and underutilized. As with auto-
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Hematopoietic Stem Cell Transplantation in Multiple Myeloma 881ransplantation, the potential beneﬁt of allotransplan-
ation must be balanced against its risk. Patients must
e fully informed of both.
educed-Intensity Regimens
The signiﬁcant risk of dying from complications
f fully ablative transplantation stimulated exploration
f reduced-intensity preparative regimens for allo-
ransplantation. The Seattle group utilized a nonabla-
ive regimen of 200 cGy TBI and ﬂudarabine with
osttransplant immunosuppression with mycopheno-
ate and cyclosporine in a small series of patients,
any with advanced myeloma [59,60]. Safety was
emonstrated, but no durable complete responses
ere obtained. Other groups have used various re-
uced-intensity regimens to achieve lower TRM,
owever, relapse rates are much higher than for stan-
ard preparative regimens and PFS appears similar or
nferior to that with myeloablative transplants [60,61].
atients with aggressive disease and plasmacytomas
are particularly poorly. As with ablative transplanta-
ion, poor functional status, advanced disease, and
hemoresistant disease are adverse risk factors for
RM, PFS, and OS [62].
equential Autologous and Nonablative
llogeneic Transplantation
Temporal separation of the high-dose preparation
nd the immune effects of the allograft (Figure 1) may
e a safer way to provide potentially curative therapy
63-66]. TRM of 10% to 20% has been reported, but
ate TRM and relapse require further study. A pro-
pective trial by Bruno and colleagues [65] reported
uperior OS and EFS in those undergoing allograft
ollowing autograft compared to tandem autografts,
igure 1. Theory of autologous followed by nonablative allogeneic
ultiple myeloma (RM) and myeloma stem cells (RMSC) in the marr
utotransplantation, the number of malignant cells is reduced. A
reparation permits engraftment of normal donor hematopoietic ce
esults in complete donor hematopoietic chimerism.hereas a similar study in high-risk individual failed to
emonstrate such a difference [66].
URRENT OUTCOMES WITH
ONTRANSPLANT THERAPIES
Melphalan and prednisone (MP) produce re-
ponses in more than 50% of patients [67,68]. Subse-
uently developed regimens, including VBMCP (vin-
ristine, carmustine, melphalan, cyclophosphamide,
nd prednisone), high-dose steroids, and VAD (vin-
ristine-adriamycin-dexamethasone) produce similar
esponse rates [69-72]. CRs occur rarely with these
egimens.
New agents are improving treatment. Oral thalid-
mide-dexamethasone (thal-dex) resulted in signiﬁ-
antly higher rates of response than treatment with
examethasone alone [73] or intravenous VAD [74],
lthough CR was achieved in 5% of patients. The
ddition of thalidomide to MP (MPT) improves re-
ponse rate, CR rate, EFS, and OS [37,75].
The proteasome inhibitor bortezomib was more
ffective than high-dose dexamethasone in patients
ith advanced disease [76]. In a phase 1/2 trial, the
ombination of bortezomib, melphalan, prednisone,
nd thalidomide achieved CR in a striking 36% of a
ubgroup treated for ﬁrst relapse [77]. These encour-
ging results, particularly the high rate of CR, provide
basis for study in early stage disease, where a ran-
omized phase 3 trial is underway. At present, there is
nsufﬁcient long-term follow-up on patients receiving
ewer regimens to determine their effect on the ben-
ﬁt provided by transplantation.
lantation. A recipient with multiple myeloma has normal (RN) and
or to autologous transplantation. Following high-dose therapy and
ic hematopoietic stem cell transplantation following nonablative
). Immunologic eradication of recipient normal and malignant cellstransp
ow pri
llogene
lls (DN
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S. Pant and E. A. Copelan882ELEVANCE OF COMPLETE REMISSIONS
Although clinical response is desirable and is com-
only considered an accurate predictor of survival,
either the rapidity nor degree of response reliably
redicts survival [78,79]. Time to progression was a
etter predictor of survival than response to frontline
herapy for more than 1500 patients enrolled on 4
outhwest Oncology Group myeloma studies [79]. A
arge study from M.D. Anderson did show signiﬁcant
urvival beneﬁt when a PR was converted to CR or no
esponse to PR by autotransplantation [80].
The degree of response reﬂects the short-term
ffect of treatment on differentiated malignant plasma
ells, which constitute nearly the entire malignancy.
ure, however, depends on elimination of the exceed-
ngly rare self-renewing malignant stem cells from
hich the terminally differentiated malignant plasma
ells are derived [81,82]. Myeloma stem cells are bio-
ogically distinct from their differentiated counter-
arts [83,84].
The malignant stem cells are quiescent and resis-
ant to most chemotherapy, which acts predominantly
n proliferating cells. Additionally, they excrete toxic
rugs and resist apoptosis [85]. Chemotherapy may
estroy nearly all of a patient’s myeloma cells (achiev-
ng remission) without affecting malignant stem cells.
ortezomib and lenalidomide also inhibit differenti-
ted malignant plasma cells but have little effect in
itro on myeloma stem cells [82,86]. These stem cells
esult in recurrence, the timing of which depends
argely on the biologic aggressiveness of a particular
atient’s myeloma. Thus, CR may be a valid surrogate
f survival in patients with biologically indolent dis-
ase, but not in those with aggressive disease.
URRENT STATUS OF PROGNOSTIC FACTORS
Several laboratory parameters have prognostic
alue in multiple myeloma and different combinations
f factors have been used to categorize patients and
redict prognosis. Most poor-risk factors, including
eta-2 microglobulin, reﬂect a high tumor burden.
enetic constitution is the primary determinant of
iologic behavior and, therefore, inﬂuences prognosis
y a different mechanism than do measures of disease
urden. Many staging systems, including the interna-
ional staging system [87], use beta-2 microglobulin,
ut do not incorporate genetics.
Chromosome 13 deletion [del(13)] identiﬁed pa-
ients whose disease relapsed quickly following auto-
ransplantation, including those who achieved remis-
ion [25]. Although the limited numbers and low
roliferative rates of malignant plasma cells in marrow
ermit identiﬁcation, by banding techniques, of ab-
ormalities in less than 1/3 of patients, ﬂouorescence
n situ hybridization (FISH) identiﬁes genomic abnor- palities in approximately 90%. In combination with
ow beta-2 microglobulin, FISH identiﬁes a group of
atients lacking t(4;14) and del (17p), who have pro-
onged survival following tandem autotransplantation
88]. In contrast, patients with either genetic abnor-
ality and a high beta-2 microglobulin fare poorly
ith this approach. In the largest series of myeloma
atients analyzed for genomic abnormalities, the IFM
as unable to demonstrate independent prognostic
ower of del(13). Its prognostic signiﬁcance was related
o its frequent association with abnormalities such as
(4;14) and del(17p) [88]. Further, this large study did
ot ﬁnd an inﬂuence of t(11;14) on survival, in contrast
o earlier less comprehensive studies [89,90].
Because allogeneic transplantation has been
roven to be advantageous in high-risk patients with
ther hematologic malignancies, the IFM group pro-
pectively compared autologous followed by dose-re-
uced allogeneic transplantation to tandem autolo-
ous transplantation in individuals with elevated B-2
icroglobulin plus chromosome 13 abnormalities
66]. No advantage for allografting was detected. In
runo’s comparison in which treatments were as-
igned only according to the presence or absence of an
LA-identical sibling donor, neither chromosome 13
bnormalities nor B2-microglobulin levels inﬂuenced
utcome after allografting [65], which yielded signif-
cantly better survival than tandem autografts. The
uppression of graft-versus-myeloma by antithymo-
yte globulin, which was included in the preparative
egimen of the former study, might contribute to
hese different results. Response to Bortezomib does
ot seem to correlate with speciﬁc unfavorable genetic
bnormalities [91,92]. These data emphasize the need
or further study of genetic alterations, their careful
ncorporation into risk assessment, and well-conceived
tudy of their impact on speciﬁc therapeutic strategies.
ONCLUSION
Although this review summarizes available data on
SCT in multiple myeloma, it also identiﬁes areas
here critical information is unavailable. Data strongly
upport a beneﬁt in PFS and TWiSTT for early autol-
gous transplantation compared to conventional che-
otherapy. Tandem transplantation appears to chieﬂy
eneﬁt patients with a limited response to ﬁrst auto-
ransplant. Allogeneic transplantation has become
afer, and should be considered more frequently, par-
icularly for younger patients early in the course of
isease.
The inﬂuence of more effective induction regi-
ens on the beneﬁts of HSCT is uncertain. The
uestion of whether patients who enter CR with mod-
rn induction therapy beneﬁt from early autotrans-
lantation is unanswered. Current prognostic staging
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Hematopoietic Stem Cell Transplantation in Multiple Myeloma 883ystems do not adequately incorporate known genomic
berrations and the basic mechanism and clinical rele-
ance of many genetic alterations are uncertain. It is
easonable at present to use autotransplantation in
hose patients lacking high-risk genetic abnormalities
here survival is prolonged following autotransplan-
ation, and to perform tandem transplants in those
ho fail to achieve at least a very good PR. Bort-
zomib-based combination regimens should be used
arly in patients with adverse prognostic features, in-
luding genetics. All of these issues require prospec-
ive study and emphasize the need for sound, large
rospective multinstitutional trials. Substantial addi-
ional work is needed to develop better prognostic
lassiﬁcation systems to rationally study risk-adapted
herapies.
The aim of these trials is not to develop simplistic
reatment algorithms. Individually tailored treatment
s the goal: no single feature, its quantation, or some
rithmetic sum of measured features should ﬁnalize
ecisions on treatment. The constellation of individ-
al features that distinguish a patient must be consid-
red in light of clinical experience and judgment. Basic
ork can and will provide information needed to make
etter decisions.
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